Kytopen, an MIT spin-out company, and Cambridge Consultants, part of Capgemini, announce the initial release of the Flowfect™ Tx System, representing a leap forward in non-viral delivery of genetic material into cells. This breakthrough will speed the manufacture of cell therapies, an exciting category of living medicines where engineered cells tackle diseases. Kytopen will now make the Flowfect™ Tx System available to select bio-pharma partners and collaborators to accelerate their engineered cell therapy production.
Emerging cell therapies open up new and effective ways of treating disease, but difficulties in manufacturability, scalability and cost have slowed progress. Cambridge Consultants collaborates with visionary clients such as Kytopen to solve these issues, ultimately working to deliver the full promise of cell therapies to patients around the globe.
The Flowfect™ technology virtually eliminates these challenges, providing an effective, gentle process that produces billions of healthy, high-quality engineered cells in minutes. The Flowfect™ Tx System enables both process optimization and manufacturing at scale, faster and more efficiently than ever before.
The Flowfect™ Tx System features an automated, single use closed system for maximum ease of use and flexibility. This non-viral delivery technology uses continuous fluid flow combined with electric fields for high efficiency delivery of payloads such as mRNA, DNA, and CRISPR RNP complexes. The Flowfect™ technology is compatible with a variety of cells, including iPSCs, primary T cells, and other human hematopoietic cells being developed for immuno-oncology and gene editing applications. High-quality engineered cell products will ultimately translate into more effective and more accessible cell therapies for patients.
The Flowfect™ Tx System is part of a broader discovery, optimization, and manufacturing platform that also includes the Flowfect™ Array, a high throughput system that enables evaluation of hundreds of programmable configurations for identification and optimization of delivery parameters. The proprietary Flowfect™ technology delivers identical transfection parameters across platforms, enabling immediate translation from discovery to process development and manufacturing scale-up, with minimal technical risk.
Cambridge Consultants is renowned for breakthrough innovations with the potential to change the world – in this case widening access to new therapies with curative potential. The company brought its deep expertise in engineering, human factors, cell therapy manufacturing and rapid prototyping to the Flowfect™ Tx System design and build process. With a track record of working with ambitious start-ups to commercialize core technology, Cambridge Consultants is also forging a strong reputation in the fast-growing bioinnovation space, applying radical innovation across biology, process development and analytics.
These strengths were recognized by Kytopen when it engaged Cambridge Consultants in 2019 to help accelerate the engineering of its standalone Flowfect™ Tx System. Kytopen’s core technology was originally developed in Professor Cullen Buie’s laboratory at MIT before he and Kytopen CEO and Co-Founder Paulo Garcia were backed by ‘The Engine’. The “tough tech” ecosystem at The Engine and the world-class team at Kytopen have driven significant technological advances since spinning out of MIT in 2017. With an ambition to revolutionize cell engineering and widen patient access to next-generation treatments, Kytopen is working to enable efficient and cost-effective manufacture of cell therapies in days rather than weeks.
Commenting on the announcement, Paulo Garcia said: “It’s been a pleasure to collaborate with the Cambridge Consultants team to realize the vision for the Flowfect™ Tx System. The existence of a physical product that can be used at our partners’ facilities is a major milestone that will allow for powerful therapeutic collaborations. We’re excited to explore the capabilities of our Flowfect™ technology to unlock next-generation therapies requiring healthy and functional engineered cells at scale. Gene-modified cell therapies have already demonstrated curative potential and we are honored to empower our partners to help patients suffering from devastating diseases worldwide.”
Bethany Grant, Senior Vice President of R&D at Kytopen, added: “Cambridge Consultants has enabled us to expand our capabilities and team, helping us to achieve this exciting product release in a very short timeframe. The Flowfect™ Tx System is an excellent first implementation of our transformative technology.”
Mike Dunkley, Senior Vice President at Cambridge Consultants, said: “We’ve really appreciated the opportunity to work alongside the team at Kytopen in developing Flowfect™ Tx. The focus on simplicity of setup, single touch operation and intuitive UI, combined with engineering rigor and robust process control has been key. In this way we’ve delivered a system with unrivaled performance in the engineering of cells via non-viral transfection. This deliberate focus on both performance and ease of use will provide Kytopen’s bio-pharma partners with a powerful new tool to advance their cell-based therapies.”
Cambridge Consultants （剑桥顾问公司）开发突破性产品，产生和授权知识产权，并为全球的客户提供商业资讯，解决与技术相关的关键问题。60多年来，公司一直致力于帮助客户转化商业机会，包括推出市场领先的产品，进入新市场，引入新技术扩大现有市场。公司拥有超过900名员工，包括工程师、科学家、数学家和设计师，遍布于英国剑桥、美国波士顿、东京和新加坡办事处，为医疗和生命科学、工业和能源、消费和零售以及通讯和基础设施等多个行业提供解决方案。欲了解更多信息，请访问: www.cambridgeconsultants.com。
Cambridge Consultants是 Capgemini Invent （凯捷集团的创新、咨询和转型品牌）的子公司。Capgemini Invent帮助管理者设想和构建他们组织的未来。公司在全球设有30多个办事处和25个创意工作室，是一支拥有7000多名员工的强大团队，将战略、技术、数据科学和创意设计与深厚的行业专业知识和洞察力相结合，开发新的数字解决方案和未来的商业模式。
获得你想要的未来 | www.capgemini.com
Kytopen is an MIT spin-out pioneering a novel and non-viral delivery process to engineer human cells (e.g. T cells, NK cells, B-cells, Monocytes/Macrophages, CD34+ stem cells, and iPSCs) for therapeutic applications in immuno-oncology and genetic disorders. The company has demonstrated the ability to successfully deliver genetic material encoded in mRNA, DNA, and CRISPR RNP complexes to a vast array of human cells with high efficiency and high viability. The FlowfectTM System being developed can process billions of cells in minutes while maintaining health and function of the engineered cells. The FlowfectTM technology carefully synchronizes continuous fluid flow with electric fields to eliminate the harmful effects of traditional delivery via static electroporation. Kytopen is unique in that it is determined to improve patients’ lives by enabling therapeutic partners to accelerate discovery with an automated platform with a goal of reducing the manufacturing time of these cell therapies from weeks to days. High-quality engineered cell products will ultimately translate into faster and more cost-effective cell therapy access for a range of patients around the world. Kytopen has developed significant traction since it spun out from MIT in 2017, with seed funding from The Engine, Horizons Ventures, and angel investors. Additionally, the company has secured non-dilutive federal and state funding from NSF SBIR phase I/II and MassVentures START grants. The Kytopen team has grown to eight full time members, encompassing a broad range of expertise. This dedicated and multidisciplinary team has enabled the rapid demonstration of the potential impact that the FlowfectTM platforms will have in the practice of future medicine by accelerating time to clinic, reducing manufacturing cost, and providing access to patients suffering from devastating diseases. For more information, visit: www.kytopen.com